Advertisement
Advertisement
Study decoded · health · inflammation · Confirmed
Drug-Resistant Bacterial Infections Linked to 1.03 Million Deaths Worldwide in 2021
1.03M deaths in 2021204 countries trackedKlebsiella rising fastestSouth Asia hit hardest
A modeling study published in Nature Communications estimates that carbapenem-resistant Gram-negative bacterial infections were linked to 1.03 million deaths worldwide in 2021, with 220,000 of those deaths directly attributable to the drug resistance itself.
Researchers analyzed mortality data from 204 countries and territories spanning 1990 to 2021, using age-period-cohort modeling and Bayesian statistical methods to estimate two measures: associated mortality (deaths among people who had a carbapenem-resistant infection) and attributable mortality (deaths that specifically wouldn't have happened if the infection had responded to standard antibiotics). Carbapenems are a class of antibiotics doctors reserve as a last resort. In 2021, associated mortality reached 1.03 million deaths worldwide (95% uncertainty interval, 0.90 to 1.17 million), while attributable mortality reached 220,000 deaths (0.17 to 0.27 million). From 1990 through 2019, associated mortality rates rose 0.82% per year and attributable rates rose 0.90% per year. South Asia showed the fastest increases in both measures, while high-income regions declined. Among seven pathogen groups, Klebsiella pneumoniae showed the fastest-rising mortality rate, while Pseudomonas aeruginosa showed declining associated mortality but a slight rise in attributable mortality. During 2020-2021, associated mortality fell 4.71% below pre-pandemic projections, while attributable mortality showed no meaningful change.
Carbapenem-Resistant Infections Linked to 1.03 Million Deaths, 0.22 Million Directly Attributable, in 2021
The authors say separating these two measures matters because falling associated mortality can mask a stagnant resistance problem, as seen with Pseudomonas aeruginosa and during the pandemic years. Carbapenem resistance develops when bacteria acquire genes that break down the antibiotic or pump it out of the cell, and those genes can spread between bacterial species through small pieces of DNA called plasmids. That is why an infection that once responded to treatment can suddenly become harder to clear.
These are modeled estimates built from the Global Burden of Disease and GRAM antimicrobial resistance databases, not counts from death certificates, so surveillance gaps in lower-income countries mean the true numbers could fall anywhere in the reported uncertainty ranges. The study was funded by Chinese government research grants that had no role in the analysis, and the authors reported no competing interests.
Data Panel
- Who
- 204 countries and territories, all ages, both sexes, mortality data from 1990 to 2021 drawn from Global Burden of Disease and GRAM antimicrobial resistance databases
- Design
- Secondary modeling analysis using age-period-cohort decomposition and Bayesian counterfactual modeling comparing carbapenem-resistant infection deaths against no-infection and drug-susceptible-infection counterfactuals
- Dose
- Not applicable — population-level mortality modeling, no treatment or intervention tested
- Primary result
- 1.03 million associated deaths in 2021 (95% uncertainty interval, 0.90-1.17 million) and 0.22 million (220,000) attributable deaths (0.17-0.27 million)
- Secondary
- Associated mortality rates rose 0.82% per year and attributable rates rose 0.90% per year from 1990-2019; South Asia rose fastest while high-income regions declined; Klebsiella pneumoniae mortality rose fastest; associated mortality fell 4.71% below pre-pandemic projections in 2020-2021
- Funding / conflicts
- Funded by National Key Research and Development Programme of China grant 2022YFC2009802 and Taicang First People's Hospital Internal Research Project 2025-IIT-074; funders had no role in design, analysis or publication decisions; authors declared no competing interests
Dr. Axe's Take
The gap between 1.03 million and 220,000 deaths matters here: roughly a fifth of people dying with these infections die specifically because the drugs no longer work, and that number keeps climbing 0.90% a year even as overall infection deaths fall in high-income countries. Klebsiella pneumoniae's rise worries me most, since it causes common infections like pneumonia and urinary tract infections that used to be simple to treat. Keep taking antibiotics exactly as prescribed and finish the full course; never stop early or save leftover pills, since partial courses train bacteria to survive. After any antibiotic course, rebuild your gut microbiome with fermented foods like kefir and sauerkraut.
— Dr. AxeDr. Axe Quiz